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Abstract
Background: Pregnancy in patients with Parkinson disease is a rare occurrence. To the best of our knowledge, the
effect of pregnancy as well as treatment in genetically confirmed autosomal recessive juvenile parkinsonism (ARJP)
has never been reported. Here, we report the first case of pregnancy in a patient with ARJP associated with a
parkin gene mutation, ARJP/PARK2.
Case presentation: A 27-year-old woman with ARJP/PARK2 was diagnosed as having a spontaneous dichorionic/
diamniotic twin pregnancy. Exacerbation of motor disability was noted between ovulation and menstruation before
pregnancy as well as during late pregnancy, suggesting that her parkinsonism might have been influenced by
fluctuations in the levels of endogenous sex hormones. During the organogenesis period, she was only treated with
levodopa/carbidopa, although she continued to receive inpatient hospital care for assistance in the activities of daily
living. After the organogenesis period, she was administered sufficient amounts of antiparkinsonian drugs. She
delivered healthy male twins, and psychomotor development of both the babies was normal at the age of 2 years.
Conclusion: Pregnancy may worsen the symptoms of ARJP/PARK2, although appropriate treatments with
antiparkinsonian drugs and adequate assistance in the activities of daily living might enable successful pregnancy
and birth of healthy children.
Background
Pregnancy in patients with Parkinson disease (PD) is a
rare occurrence. However, physicians treating pregnant
patients with PD should be aware of the impact of preg-
nancy on parkinsonism as well as that of the treatment
for PD on pregnancy and fetal development [1,2]. To the
best of our knowledge, the effect of pregnancy in geneti-
cally-confirmed autosomal recessive juvenile parkinson-
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first case of pregnancy in a patient with ARJP associated
with a parkin gene mutation (ARJP/PARK2), which is
characterized by early onset, marked response to levo-
dopa treatment, and levodopa-induced dyskinesia [3].
Case Presentation
A 27-year-old woman with ARJP having heterozygous
exonic deletion mutations (Δexon 4/Δexons 2-4) of the
parkin gene (patient II-2 in pedigree 455) [4] was referred
to our hospital at the fifth week of gestation. This patient
showed bradykinesia, rigidity, postural instability, dystonia,
a slowly progressive course, and alleviation of symptoms
in response to levodopa therapy. She had a 15-year history
of parkinsonism and was receiving treatment with dopa-
minergic drugs, including levodopa/carbidopa (450 mg/
day), entacapone (400 mg/day), selegiline (7.5 mg/day),
and ropinirole (1.5 mg/day). Wearing-off phenomenon
and levodopa-induced dyskinesia were noted since the age
of 24 years. The wearing-off phenomenon became remark-
able gradually. The duration of levodopa action was about
120 min. Treatment with entacapone increased the dura-
tion of the “on” period. The Hoehn and Yahr stage was
5 during the “off” period and 2 during the “on” period.
Moderate dyskinesia with pain was prominent at the peak
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ism tended to fluctuate depending on the menstrual cycle
since the age of 21 years: it exacerbated between ovulation
and menstruation.
She was diagnosed as having a spontaneous dichorionic/
diamniotic twin pregnancy. To reduce the teratogenic risk
of antiparkinsonian drugs [5], we eventually discontinued
them except levodopa/carbidopa (450 mg/day) until the
sixth week of gestation. Thereafter, her dyskinesia disap-
peared almost completely during the course of gestation.
Because the patient complained of worsening of her motor
disability (Hoehn and Yahr stage [on/off] 3/5) and felt
strong anxiety due to her inability to move during off-time
and in the night, she received inpatient hospital care for
assistance in the activities of daily living (ADL) without
increasing the dose of the antiparkinsonian drugs. How-
ever, her motor disability worsened after the 19
th week of
gestation (Hoehn and Yahr stage [on/off] 4/5) and the
wearing-off phenomenon became remarkable after the
21
st week of gestation. Thus, we gradually increased the
dose of levodopa/carbidopa up to 700 mg/day and
resumed entacapone and selegiline at doses of 400 mg/day
and 7.5 mg/day, respectively.
At the 35
th week of gestation, the patient underwent
caesarean delivery due to preterm premature rupture of
the membranes and onset of labor pains. She delivered
healthy male twins weighing 2,184g and 2,022g with 5-
min Apgar scores of 8 and 9, respectively. Examination of
the babies revealed no abnormalities except ventricular
septum defect in one of the babies. Because the diameter
of the VSD measured by using transthoracic echocardio-
graphy was small (3 mm), it was considered that this VSD
did not need surgical repair. The babies were fed synthetic
milk to avoid exposure to antiparkinsonian drugs, because
medical information on this topic is lacking. After dis-
charge from our hospital, the patient could care for the
babies with assistance from her family. Psychomotor
development of both the babies was normal at the age of
2 years.
Conclusions
In this report, we present the case of a twin pregnant
patient with ARJP/PARK2. It remains unknown whether
the twin pregnancy was associated with the exposure to
several antiparkinsonian drugs taken during early preg-
nancy. Whether the twin pregnancy was associated with
the exposure to several antiparkinsonian drugs taken
during early pregnancy remains unknown, because a
causal association between antiparkinsonian drugs and
multiple ovulations has not yet been established.
We also present several important findings in preg-
nant PD patients. First, we speculated that parkinsonism
associated with ARJP/PARK2 might be influenced by
the levels of sex hormones. In our patient, exacerbation
of motor disability was noted between ovulation and
menstruation before pregnancy as well as during late
pregnancy. Because estrogen increases during such con-
ditions and because estrogen is known to regulate the
dopaminergic neurotransmission in the basal ganglia [6],
estrogen may be considered to exert an influence on
parkinsonism. However, there is a possibility that the
motor disability noted during late pregnancy could be
related to pregnancy-induced pharmacokinetic variations
of drug levels [6].
Second, programmed pregnancy might be recom-
mended to PD patients to reduce the risk of teratogeni-
city. We considered that monotherapy with levodopa/
carbidopa might be preferable during the organogenesis
period, because this drug combination has been shown
to have no adverse effect on the fetus [7]. However,
because monotherapy with levodopa/carbidopa could
increase parkinsonism and the off-time duration, ade-
quate ADL assistance should be provided to the patients
during this period. With regard to the presence of a
VSD in one of the twins, a potential role of medication
effect of antiparkinsonian drugs needs to be considered.
However, because this anomaly is not very rare (the pre-
valence of muscular VSD in neonates is 53.2/1000 live
births [8]), it is difficult to conclude that VSD is caused
by antiparkinsonian drugs.
Finally, after the organogenesis period, patients should
be administered sufficient amounts of antiparkinsonian
drugs to improve their parkinsonism symptoms and the
wearing-off phenomenon, because a worsened clinical
status may have a profound impact on the maintenance
of pregnancy, delivery, and the ability of PD patients to
care for their babies [9].
In conclusion, pregnancy may worsen the symptoms
of ARJP/PARK2, although appropriate treatments with
antiparkinson drugs and adequate ADL assistance might
enable successful pregnancy and birth of healthy
children.
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